Sarah Sallon ^Leaders

Experienced Vice President of Translational Science with a demonstrated history of working in academia, big pharma and the precision medicine software industry. Strong research professional skilled in Molecular Biology, Next-gen Sequencing, Life Sciences, Research, and Genomics. Following his postdoctoral work, Steve joined Eli Lilly and Company as a research scientist in cancer genetics and genomics. There he led efforts using next-generation sequencing to identify genetic biomarkers of cancer drug sensitivity and resistance. Steve left Eli Lilly to take a position as principal scientist at the startup precision-health company, LifeOmic, to develop precision oncology tools. At LifeOmic, Steve is now the vice president of translational science leading efforts to integrate genomic and phenotypic data for precision health in cancer and beyond. He is particularly passionate about improving wholistic care for cancer patients across the entire care continuum from prevention to treatment and survivorship. He strongly believes the future of precision health will leverage technology together with increasingly affordable tools like multi-omic profiling to tailor interventions for personal health and wellness.